Optimizing supercritical antisolvent process parameters to minimize the particle size of paracetamol nanoencapsulated in L-polylactide
Mahshid Kalani, Robiah Yunus, Norhafizah Abdullah
Chemical and Environmental Engineering, Faculty of Engineering, University Putra Malaysia, Selangor Darul Ehsan, Malaysia
Background: The aim of this study was to optimize the different process parameters including pressure, temperature, and polymer concentration, to produce fine small spherical particles with a narrow particle size distribution using a supercritical antisolvent method for drug encapsulation. The interaction between different process parameters was also investigated.
Methods and results: The optimized process parameters resulted in production of nanoencapsulated paracetamol in L-polylactide with a mean diameter of approximately 300 nm at 120 bar, 30°C, and a polymer concentration of 16 ppm. Thermogravimetric analysis illustrated the thermal characteristics of the nanoparticles. The high electrical charge on the surface of the nanoparticles caused the particles to repel each other, with the high negative zeta potential preventing flocculation.
Conclusion: Our results illustrate the effect of different process parameters on particle size and morphology, and validate results obtained via RSM statistical software. Furthermore, the in vitro drug-release profile is consistent with a Korsmeyer–Peppas kinetic model.
Keywords: supercritical, antisolvent, encapsulation, nanoparticles, biodegradable polymer, optimization, drug delivery
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]